Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults

By Sabela Ojea

Invivyd said the U.S. Food and Drug Administration granted emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.

The biotechnology company on Friday said that the authorization of Pemgarda, administered as an intravenous infusion, targets people aged at least 12 weighing at least 40 kilograms, or about 88 pounds.

Recipients shouldn't be infected with the Covid or have had a recent exposure to an individual infected with the virus ahead of the intravenous infusion, Invivyd said.

The company said people who are immunocompromised continue to be disproportionally affected by Covid, even after receiving multiple vaccine doses.

Write to Sabela Ojea at [e-mail]

(END) Dow Jones Newswires

03-22-24 1541ET